HORSHAM, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, will release second quarter ended June 30, 2020 financial results on Tuesday, August 11th before the market opens. STRATA Skin Sciences President and Chief Executive Officer, Dr. Dolev Rafaeli, and Matthew C. Hill, Chief Financial Officer, will host a conference call at 8:30 am Eastern time to review the Company’s progress.
| Conference Call Details: | |
| Date: | Tuesday, August 11 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 877-451-6152 |
| International: | 201-389-0879 |
| Israel: | 1 809 406 247 |
| Passcode: | 13707396 |
| Webcast: | www.strataskinsciences.com |
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
The Company’s proprietary XTRAC® excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases, which impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.
STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.
The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 822 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10-mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.
Investor Contacts:
| Matthew Hill, Chief Financial Officer | Chuck Padala, Managing Director | |
| STRATA Skin Sciences, Inc. | LifeSci Advisors, LLC | |
| 215-619-3200 | 646-627-8390 | |
| ir@strataskin.com | chuck@lifesciadvisors.com |